A historic multilateral effort co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization (WHO) and UNICEF from 2020 through 2023, COVAX pushed to centre vaccine equity at the heart of the global response to the COVID-19 pandemic. COVAX will come to a close on 31 December 2023.

OWP logo


COVAX in numbers

Participants 195 participating economies
Delivery ~2 billion vaccines and safe injection devices shipped to 146 economies
Pandemic ~2.7 million deaths averted
Vial 10 different COVID-19 vaccine products shipped
Petri dish >US$ 12 billion to support access for lower-income economies

History and milestones

“No one is safe until everyone is safe”: Key moments in the evolution of the COVAX Facility – the global risk-sharing mechanism for pooled procurement and equitable distribution of vaccines at the heart of COVAX.

See timeline

Key learnings

View page

COVAX: key learnings for future pandemic preparedness and response

WHITE PAPER | 14 September 2022

Drawing on COVAX’s unique experience enabling an unprecedented global rollout at scale during a pandemic, this paper outlines the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for the future.


A preliminary assessment of COVAX’s impact in lower-income countries

A preliminary assessment of COVAX’s impact in lower-income countries

WHITE PAPER | May 2023

Approximately 90% of COVAX-delivered COVID-19 doses have gone to lower-income economies. This represents the fastest and most complex global deployment of vaccines ever. But in terms of achieving equitable access during this pandemic, how successful has it been and where have its impacts been the greatest?


Coordination in a crisis: Lessons managing the COVAX Strategic Coordination Office (2021–2023)

Coordination in a crisis: Lessons managing the COVAX Strategic Coordination Office (2021–2023)

WHITE PAPER | December 2023

Drawing upon experiences gained during the COVID-19 pandemic in coordinating the COVAX Strategic Coordination Office (SCO), this paper proposes lessons for future pandemic responses, as well as what might be maintained during intra-pandemic periods, to better prepare for future emergencies.


Building an emergency response decision-making framework for outbreaks of pandemic potential

Building an emergency response decision-making framework for outbreaks of pandemic potential


When an outbreak of an infectious disease starts to escalate, how should global health organisations decide on if, when and how to launch a response? To this end, Gavi is working with partners to develop a decision-making framework for outbreaks of pandemic potential that will define optimum interventions, specific to the outbreak, and unlock critical financing in response.


The African Vaccine Manufacturing Accelerator: what is it and why is it important?

The African Vaccine Manufacturing Accelerator: what is it and why is it important?


A new innovative financing instrument, called the African Vaccine Manufacturing Accelerator (AVMA), has been approved by the Gavi Board. But why is it important for African countries to produce vaccines, how will it work, and why now?

Read article

View page

Expanding Sustainable Vaccine Manufacturing in Africa 2022

WHITE PAPER | 2 November 2022

The pandemic has highlighted new and pressing challenges to regional vaccine supply resilience as a critical factor in global health security. While 1.8 billion doses1 of COVID-19 vaccine have been shipped under COVAX, including 0.6 billion to Africa, early delays in obtaining doses on the African continent stimulated new resolve to address future supply security.


View page

A New Era of Vaccine Manufacturing in Africa

WHITE PAPER | 22 June 2022

One of the prominent issues exposed by the COVID-19 pandemic is the urgent need to further diversify global vaccine manufacturing, particularly with regards to Africa. With the political realities of nationalism, trade barriers, and the absence of regional manufacturing capability and capacity, rapid and equitable global access to life-saving vaccines can be compromised, leading to delays that put lives at risk.


View page

Taking stock of humanitarian access to pandemic vaccines


COVAX was launched in 2020 with equity as its foundational principle, and fundamental to its design from the outset was a vision to address the most unpredictable and hardest to fill gaps in global COVID-19 vaccine access.


View page

10 Learnings for the Alliance from the COVAX Humanitarian Buffer

DISCUSSION PAPER | February 2023

The following 10 learnings highlight the ways in which the COVAX Humanitarian Buffer (HB) and COVAX’s broader learnings in reaching humanitarian settings can contribute to both the Alliance’s work in routine immunisation, future preparedness and response efforts.


Country perspectives

People with Long COVID three times more likely to give up work

Study highlights the toll of ongoing COVID-19 symptoms on the workforce.

We finally know why some people got COVID while others didn’t

In a human ‘challenge trial’ volunteers were deliberately infected with COVID to get the answer.

Preparing for the unknown: how the world can get ready for the next pandemic

South African infectious diseases expert Professor Salim Abdool Karim explains how the world can prepare for the next pandemic – even if we don’t yet know what it will be.

How digital communication can help drive vaccine demand and healthcare access

What a person’s future looks like depends on their access to universal rights like healthcare. Access Challenge is an organisation transforming communities through digital media. Here is what we can learn from their COVID-19 campaigns in Tanzania…

Gavi's impact in Africa since 2000

Through our current partnerships with 39 African countries in 2024, Gavi supports routine immunisation programmes to give children an equal chance of a healthier and more productive future.

How to get vaccines to remote areas? In Sierra Leone they’re delivered by foot, boat or motorbike

For villagers in remote areas in Sierra Leone it takes a lot of time and money to get to a clinic. So the COVID-19 vaccine came to the people.

Failure to define Long COVID will impede research progress

Surveys that assess symptoms for long Covid have been inadequate for developing a case definition for the illness.

Nearly 7% of Americans struggle with Long COVID as infections surge

The post-viral illness continues to damage lives as global numbers are estimated to be at least 65 million.

Four key pieces of research on Long COVID that have improved our understanding

Four years since the start of the pandemic, we now have a good understanding of what Long COVID does. More of a mystery has been why it happens. New research is starting to find answers.

As the pandemic turns four, here’s what we need to do for a healthier future

On the fourth anniversary of the pandemic, a public health researcher offers four principles for a healthier future.

COVID-19 rapid tests still work against new variants – researchers keep ‘testing the tests,’ and they pass

Research shows that rapid antigen tests are performing as well at detecting the most recent dominant variants as they did with the earliest strains in the COVID-19 pandemic.

Mounting research shows that COVID-19 leaves its mark on the brain, including with significant drops in IQ scores

Two new high-profile studies add to the increasingly worrisome picture of how even mild cases of COVID-19 can have detrimental effects on brain health.

  • Ghana
  • CAR
  • Indonesia
  • Saudi Arabia
  • Spain
  • Canada
  • Asian Development Bank

COVAX data brief

Regular snapshot of latest information on key COVAX data points, including shipments, donations, coverage, administration, absorption and delivery support.

Explore COVAX

COVAX Facility

Managing the end-to-end coordination of COVAX, ensuring pooled procurement and equitable distribution of COVID-19 vaccines around the world.


The Gavi COVAX Advance Market Commitment (AMC) ensured access to COVID-19 vaccines and support for lower-income countries.

COVAX in humanitarian settings

Addressing the most unpredictable and hard-to-fill gaps in access.

Last updated: 14 May 2024

Subscribe to our newsletter